As a result of multiple whistleblower lawsuits, Pfizer, Inc. has paid a hefty price to settle allegations of defrauding Medicare, Medicaid, and other government-funded health care programs. Attorneys from Kenney& McCafferty represented the whistleblowers in the cases, which concerned Pfizer’s marketing of four of its drugs — including Geodon and Zyvox.
In the case of Geodon, Pfizer agreed to pay $300 million to resolve allegations that it engaged in off-label marketing for the anti-psychotic medication. Geodon is FDA-approved only to treat patients ages 18-65 diagnosed with schizophrenia or acute manic or mixed episodes associated with bipolar disorder. According to the whistleblower suit, Pfizer illegally promoted use of Geodon for a variety of off-label conditions, including depression, mood disorder, anxiety, aggression, dementia, ADHD, OCD, autism, and PSD. The company also marketed the drug for pediatric, adolescent and geriatric patients.
The allegations were made in a qui tam lawsuit filed by K&M attorneys, Brian Kenney and Tavy Deming, on behalf of Harrisburg psychiatrist, Dr. Stefan Kruszewski. According to Kenney, Pfizer targeted children to expand off-label use and maintained more than 250 child psychiatrists on its payroll.” Kenney stated that “the intent of paying so many child psychiatrists was to gain a foothold within the fastest growing market for antipsychotics — children.”
Geodon’s most dangerous side effect is its potential to affect the heart’s rhythm, a condition known as QT prolongation, which can greatly increase the risk of sudden cardiac death. The company’s off-label promotion of the drug was deemed especially dangerous, because its safe use by children had not been evaluated or approved.
In a case filed by Ronald Rainero, a former Pfizer sales manager from New Jersey,
Pfizer also agreed to pay $100 million to resolve allegations that it improperly marketed its antibiotic, Zyvox. The drug was marketed for a variety of off-label conditions beyond the specific types of infections for which it was FDA-approved. The complaint alleged that Pfizer made and/or disseminated unsubstantiated and/or false representations or statements about the safety and efficacy of Zyvox in order to further the off-label campaigns.
According to K&M’s Deming, even though it is illegal for drug makers to engage in off-label promotion, they find ways to do so because there is so much money to be made from the practice. As Pfizer discovered, there can also be a stiff penalty.
Truly in the upper echelon.
Kenney & McCafferty are experts in this area. They know the healthcare and drug industry well.
Kenney & McCafferty are SMART and CREATIVE. They think outside of the box.
When contemplating this particular area of specialty pharma, I went to Kenney & McCafferty.
Kenney & McCafferty provided confidence, and knowledge, and were truthful.
My overall experience working with Kenney & McCafferty was excellent and very satisfying. They are responsive and spend an impressive amount of time on each case.
Kenney & McCafferty does this and only this, and they win.
It’s easy to file a qui-tam case; it’s hard to win one. Kenney & McCafferty wins.
A very well respected person in the qui tam industry explained to me that there may be 400 lawyers in the country that do this type of work, only 200 do it regularly, only 100 do it full time and only 25 are rock stars– and that’s Kenney & McCafferty.
Their success is the best differentiator.
What differentiates Kenney & McCafferty from competitors is their success and experience. They are very good at what they do and a pleasure to work with.
The devil is in the details with these cases, so to demonstrate that critical knowledge is key